Aprogen Biologics Inc. (KRX:003060)
810.00
-9.00 (-1.10%)
Feb 21, 2025, 9:00 AM KST
Aprogen Biologics Revenue
Aprogen Biologics had revenue of 14.53B KRW in the quarter ending September 30, 2024, a decrease of -27.83%. This brings the company's revenue in the last twelve months to 68.03B, down -16.77% year-over-year. In the year 2023, Aprogen Biologics had annual revenue of 87.36B with 34.01% growth.
Revenue (ttm)
68.03B
Revenue Growth
-16.77%
P/S Ratio
1.10
Revenue / Employee
180.46M
Employees
377
Market Cap
160.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 87.36B | 22.17B | 34.01% |
Dec 31, 2022 | 65.19B | 8.71B | 15.42% |
Dec 31, 2021 | 56.48B | 3.16B | 5.93% |
Dec 31, 2020 | 53.32B | 2.42B | 4.75% |
Dec 31, 2019 | 50.90B | 5.51B | 12.13% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Peptron | 2.41B |
Hanall Biopharma | 134.24B |